Procore signs multi-year strategic collaboration agreement with AWS
LONDON - LungLife AI, Inc. (AIM:LLAI), a company specializing in clinical diagnostic solutions for lung cancer, announced today that its shareholders have approved two key resolutions during a Special Meeting. The first resolution authorizes the cancellation of the company’s shares from trading on the AIM market, and the second approves an exclusive license and distribution agreement with Circulogene Theranostics, Inc.
The proxy votes showed overwhelming support for both resolutions, with 95.2% in favor of delisting from AIM and a unanimous vote for the agreement with Circulogene Theranostics. The cancellation of the Common Shares from AIM is scheduled for 7:00 a.m. on May 29, 2025, making May 28 the last day of trading for the company’s shares on the market.
The authorization of the transaction with Circulogene Theranostics paves the way for LungLife AI to proceed with the completion of the agreement. The company is currently coordinating with relevant stakeholders to obtain the necessary consents for completion, which is anticipated to occur in the second quarter of 2025, following the AIM delisting date.
The details of both the delisting and the exclusive license and distribution agreement were initially provided in a company announcement and a circular published on April 29, 2025. These documents are accessible on LungLife AI’s website for those seeking further information.
This move comes as part of LungLife AI’s strategic initiatives to realign its business operations and partnerships. The company’s focus remains on advancing diagnostic solutions for lung cancer, a leading cause of cancer-related deaths worldwide.
The information presented in this article is based on a press release statement from LungLife AI, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.